These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 35019731)
41. Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals. Shephard A; Kolaczkowski L; Barker N; Nahal D; Oreja-Guevara C; Reyes S; Gray H; Salloukh H; Giovannoni G Neurol Ther; 2024 Aug; 13(4):1015-1038. PubMed ID: 38760637 [TBL] [Abstract][Full Text] [Related]
42. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods]. Meuth SG; Ruck T; Aktas O; Hartung HP Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912 [TBL] [Abstract][Full Text] [Related]
43. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. De Stefano N; Giorgio A; Battaglini M; De Leucio A; Hicking C; Dangond F; Giovannoni G; Sormani MP Mult Scler; 2018 Feb; 24(2):222-226. PubMed ID: 28140753 [TBL] [Abstract][Full Text] [Related]
44. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S; Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565 [TBL] [Abstract][Full Text] [Related]
45. [Recommendations for the use of cladribine tablets in recurring multiple sclerosis]. Oreja-Guevara C; García-Merino JA; Saiz A; Rodríguez-Antigüedad A; Álvarez-Cermeño JC; Estrada-Pérez V; Izquierdo G; Fernández O Rev Neurol; 2019 Dec; 69(s02):1-9. PubMed ID: 31933293 [TBL] [Abstract][Full Text] [Related]
46. Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Freedman MS; Coyle PK; Comi G; L Scarberry S; Damian D; Hyvert Y; Dangond F; Galazka A; Jack D; Lebson LA; Leist TP Mult Scler J Exp Transl Clin; 2021; 7(1):2055217321990852. PubMed ID: 33717501 [TBL] [Abstract][Full Text] [Related]
47. Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment. Schönfelder K; Schuh H; Pfister F; Krämer J; Eisenberger U; Skuljec J; Hackert J; Ruck T; Pfeuffer S; Fleischer M; Gäckler A; Hagenacker T; Kribben A; Meuth SG; Kleinschnitz C; Pul R Mult Scler; 2021 Oct; 27(12):1960-1964. PubMed ID: 34165361 [TBL] [Abstract][Full Text] [Related]
56. [Cladribin. Development of an oral formulation for the treatment of multiple sclerosis]. Hartung HP; Kieseier BC; Aktas O Nervenarzt; 2010 Feb; 81(2):194-202. PubMed ID: 20127230 [TBL] [Abstract][Full Text] [Related]
57. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Afolabi D; Albor C; Zalewski L; Altmann DR; Baker D; Schmierer K Mult Scler; 2018 Oct; 24(11):1461-1468. PubMed ID: 28817997 [TBL] [Abstract][Full Text] [Related]
58. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Patti F; Visconti A; Capacchione A; Roy S; Trojano M; Ther Adv Neurol Disord; 2020; 13():1756286420922685. PubMed ID: 32587633 [TBL] [Abstract][Full Text] [Related]
59. [A plan for risk management in the treatment of multiple sclerosis with movectro (cladribine tablets)]. Khachanova NV Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):99-104. PubMed ID: 21916164 [No Abstract] [Full Text] [Related]
60. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. Hettle R; Harty G; Wong SL J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]